share_log

HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50

Benzinga ·  Oct 2, 2023 07:01

HC Wainwright & Co. analyst Joseph Pantginis maintains Biora Therapeutics (NASDAQ:BIOR) with a Buy and lowers the price target from $65 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment